Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases

NCT00393965 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Brain Neoplasms

Interventions

DRUG: MPC-6827

Sponsor

Myrexis Inc.